What is the value of maintenance therapy in advanced NSCLC, and who should get it?


We've covered the question of maintenance therapy for lung cancer in many posts over the past 5-6 years as it has evolved from a concept with little evidence to a standard of care, but it is difficult to get a good summary of the big picture. This presentation is my attempt to distill the field into the most important principles.


Dr. Leighl on Maintenance Therapy as Last Highlight of Lung Cancer from 2012


PARAMOUNT SchemaThe last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta.

Subscribe to Continuation maintenance